

[View this email in your browser](#)



## STUDY MATTERS

---

March 3, 2022

Wake NCORP Website: <https://wakencorp.phs.wakehealth.edu/>

---

### **NCORP BIOSPECIMEN LAB UPDATE:**

*The lab has moved!*

**NEW \*REVISED\* SHIPPING ADDRESS**

K. KOURMAN & M. MORRIS

NCORP Biospecimen Lab

Phone: 336-716-2581

Bldg A1A Lab 230 c/o Delivery on Time

Wake Forest School of Medicine

RICHARD DEAN Bldg RECEIVING DOCK

391 TECHNOLOGY WAY

WINSTON SALEM NC 27101

New air bills will be printed and sent to sites for old kits. New kits going out soon will have the new return address.

---

## **For Funding Opportunities Announcements Relevant to NCORP CCDR, click on this link:**

<https://healthcaredelivery.cancer.gov/funding/opportunities.html>

---

### **2022 Landscape Assessment Webinars:**

On behalf of the 2022 Landscape Assessment Committee, we would like to invite you to join us for a webinar that will discuss the 2022 Landscape survey. The target audience of this webinar should include NCORP Administrators, CCDR Leads, and applicable research staff. This webinar will cover the purpose of the survey, the key domains that are covered, how items were reviewed and finalized, and the data collection process once the survey is live.

Thursday, March 10, 2022 at 3 pm EST

#### **WebEx Invite for March 10th Session:**

Join from the meeting

link: <https://wakehealth.webex.com/wakehealth/j.php?MTID=m6577f4a2e4d16ab1be17cd74d58c5f7d>

Join by meeting number: Meeting number (access code): 2434 335 8154

Meeting password: 2sDddASeM48

Join by phone

+1-415-655-0001 US Toll

---

## Upcoming Site Calls

### **WF-1901 - IMPACTS - Internet-delivered Management of Pain Among Cancer Treatment Survivors**

Site Call scheduled for March 9, 2022 will be cancelled. Stay tuned for a webinar invitation when Amendment #5 is activated.

### **WF-1802 - PCW - Influence of Primary Treatment for Prostate Cancer on Work Experience**

March 15, 2022 at 1:30pm EDT

### **WF-97415 - UPBEAT - Understanding and Predicting Breast Cancer Events after Treatment**

March 16, 2022 at 1:00pm EDT

### **WF-1805CD - HN-STAR - Implementation and Effectiveness Trial: HN-STAR**

March 16, 2022 at 3:00pm EDT

### **WF-1804CD - AH-HA - Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors**

March 17, 2022 at 11:30am EDT

### **WF-1801 - Ramipril - A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy**

March 23, 2022 at 3:00pm EDT

### **WF-1806 - M&M - Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer**

April 13, 2022 at 2:30pm EDT

If you would like to attend, but did not receive an invitation, please email [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu)

---

Please email [7NCORP@wakehealth.edu](mailto:7NCORP@wakehealth.edu) when shipping biospecimen samples. Include the FEDEX tracking number in your email so that misplaced samples can be tracked before they spoil.

---

## Study Updates

---

### [WF-1801 - Ramipril - A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma \(GBM\) Patients Receiving Brain Radiotherapy](#)

#### [Amendment 6, Protocol Version Date 12/08/2021 was released 03/01/2022](#)

The WF NCORP Research Base study titled *A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy* (WF-1801) has been amended (Amendment 6, Protocol Version Date 12/08/2021). The amended protocol and related documents have been released as of **March 1, 2022** and are available on the [CTSU](#) website. The OPEN enrollment form will be updated and posted on the [WAKENCORP](#) site.

A brief summary of the updates with this amendment is listed below. Other changes are listed in the Summary of Changes document that is posted to CTSU.

- Exclusion criteria were updated to include Memantine, Donepezil, and/or other

medications prescribed to enhance cognition.

- Inclusion criteria were updated to expand window when Ramipril is given from 21-35 days after surgery to 21-42 days after surgery.
- Sites will now be allowed to use local labs as a substitute for LabCorp to increase flexibility and decrease time required for results.
- Clarified AE/SAE reporting language.
- Temozolomide documentation was updated.
- New study flyer and patient/family brochure were created to promote the study.
- New informational sheet for PIs was created.

**Note - Limited Access Case Report Forms:** Online access to CRF 17-20 (Baseline Assessment, 6 Week Assessment, 10 Week Assessment, 22 Week Assessment) is restricted to neurocognitive test certified site personnel only and can be downloaded from the Protocol Documents page of the Wake Forest NCORP Research Base (WF NCORP RB) member website, [WAKENCORP](#). For site staff who have questions or need to complete the neurocognitive test certification, please contact the WF NCORP RB at [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu).

**Sites interested in participating** should contact [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu), Attn: WF-1801

---

## **WF-1805CD - HN-STAR - Implementation and Effectiveness Trial of HN-STAR**

Thank you all who joined us for our recent series of refresher trainings! These trainings are now available on the [Wake NCORP website](#).

We are pleased to announce that we will be offering travel awards to the top two accruing sites between January 19 and July 31, 2022. Each award will cover two nights' accommodations at the Wake Forest NCORP 2022 Annual Meeting in Myrtle Beach, SC at the Marriott Grand Dunes in October.

---

## **WF-1806 - M&M - Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer**

Starting March 1, 2022, win M&M's in the mail! These will go to:

- The first site to enroll a participant each month
- The site who enrolls the most participants between bi-monthly site calls



---

## **WF-97415 - UPBEAT - Understanding and Predicting Breast Cancer Events after Treatment**

When shipping Serum, Plasma, and DNA samples to the Biospecimen Lab, please change the Express Package Service selection from "FedEx Standard Overnight" to "FedEx Priority Overnight"

Several samples have been arriving late to our Biospecimen lab due to delays encountered through FedEx shipping.

As always, please do not ship samples for the WF97415-UPBEAT study on Friday as they will not be processed at the lab until the following Monday. Samples that thaw to room temperature are no longer evaluable.

New kits received from the Biospecimen Lab will have the correct shipping service

indicated.

Please contact [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu) if you have any questions.

---

### Accruals as of March 2, 2022

Open Studies	Name	Enrolled (Patients)	Target (Patients)	Enrolled (Non-Patients)	Target (Non-Patients)
WF-1801	RAMIPRIL	50	75		
WF-1802	PCW	184	255		
WF-1806	M&M	73	300		
WF-1901	IMPACTS	40	456	0	40
WF-1804CD	AH-HA	313	600	19	40
WF-1805CD	HN STAR	48	350	67	140

---

*Copyright © 2022 Wake Forest NCORP Research Base, All rights reserved.*

You were added to this email list when you were rostered to the WAKE NCORP Research Base

**Our mailing address is:**

Wake Forest NCORP Research Base  
Medical Center Blvd  
Winston Salem, NC 27157-0001

[Add us to your address book](#)

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe from this list](#).

